Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 May 30;14(5):1169-1173.
doi: 10.21037/tau-2025-93. Epub 2025 May 27.

Metastatic renal cell carcinoma disease response in the era of immune checkpoint inhibitor-based combinations

Micah Ostrowski  1 , Georges Gebrael  1 , Benjamin L Maughan  1
Affiliations
Editorial

Metastatic renal cell carcinoma disease response in the era of immune checkpoint inhibitor-based combinations

Micah Ostrowski et al. Transl Androl Urol. .
No abstract available

Keywords: Immunotherapy; disease assessment; metastatic; renal cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2025-93/coif). B.L.M. reports paid consultant/advisor to Abbvie, Pfizer, AVEO oncology, Janssen, Astellas, Bristol-Myers Squibb, Clovis, Tempus, Merck, Exelixis, Bayer Oncology and Peloton Therapeutics; Huntsman Cancer Institute has received research funding from Exelixis (Inst), Bavarian-Nordic (Inst), Clovis (Inst), Genentech (Inst) and Bristol-Myers Squibb (Inst) on his behalf. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med 1998;338:1272-8. 10.1056/NEJM199804303381805 - DOI - PubMed
    1. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41. 10.1200/JCO.2005.03.206 - DOI - PubMed
    1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24. 10.1056/NEJMoa065044 - DOI - PubMed
    1. Motzer RJ, Hutson TE, Tomczak P, et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol 2023;41:1965-71. 10.1200/JCO.22.02623 - DOI - PubMed
    1. Gulati S, Labaki C, Karachaliou GS, et al. First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape. Oncologist 2022;27:125-34. 10.1093/oncolo/oyab056 - DOI - PMC - PubMed